AB Corporate Bond ETF (NASDAQ:EYEG) Shares Cross Below 200 Day Moving Average – Should You Sell?

AB Corporate Bond ETF (NASDAQ:EYEG)’s stock price crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $35.56 and traded as low as $35.31. AB Corporate Bond ETF shares last traded at $35.3150, with a volume of 42 shares trading hands.

AB Corporate Bond ETF Stock Performance

The firm has a market capitalization of $28.25 million, a PE ratio of -21.02 and a beta of 0.17. The company has a quick ratio of 3.07, a current ratio of 3.07 and a debt-to-equity ratio of 0.01. The company has a 50-day moving average of $35.26 and a 200 day moving average of $35.56.

AB Corporate Bond ETF Increases Dividend

The business also recently disclosed a monthly dividend, which was paid on Thursday, June 4th. Investors of record on Monday, June 1st were given a $0.1415 dividend. This represents a c) annualized dividend and a dividend yield of 4.8%. This is a positive change from AB Corporate Bond ETF’s previous monthly dividend of $0.14. The ex-dividend date was Monday, June 1st. AB Corporate Bond ETF’s dividend payout ratio (DPR) is currently -102.98%.

Institutional Investors Weigh In On AB Corporate Bond ETF

Hedge funds have recently bought and sold shares of the stock. Kestra Advisory Services LLC bought a new position in shares of AB Corporate Bond ETF in the 4th quarter worth $34,000. Jane Street Group LLC purchased a new stake in shares of AB Corporate Bond ETF during the 2nd quarter valued at $232,000. Finally, Wealth Enhancement Advisory Services LLC lifted its holdings in shares of AB Corporate Bond ETF by 32.5% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 157,702 shares of the specialty pharmaceutical company’s stock worth $5,634,000 after acquiring an additional 38,685 shares during the last quarter. 64.16% of the stock is currently owned by institutional investors.

About AB Corporate Bond ETF

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.